Addiction & Health

https://ahj.kmu.ac.ir
10.34172/ahj.1641
AHJ. 2025;17:1641

Review Article

Pulmonary Complications of Substance Abuse: Pathophysiology, Diagnosis, and Management Strategies

Fariba Shahi[1], Roya Rafaiee[2], Niloofar Keikhaei[3], Seyedeh Hatameh Asadinejad Tahergourabi[4], Hamid Jomehpour[5], Hamid Kalalian-Moghaddam[6], Mohammad Niroumand Sarvandani[7], Raheleh Rafaiee[8*]

[1]Department of Clinical Psychology, Science and Research Branch, Islamic Azad University, Tehran, Iran
[2]Department of Internal Medicine, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
[3]Department of Internal Medicine, School of Medicine, Sayyad Shirazi Hospital, Golestan University of Medical Sciences, Gorgan, Iran
[4]Department of Pulmonary Medicine, Hazrate-Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
[5]Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
[6]Center for Health Related Social and Behavioral Sciences Research, Shahroud University of Medical Sciences, Shahroud, Iran
[7]Social Development and Health Promotion Research Center, Gonabad University of Medical Sciences, Gonabad, Iran
[8]Psychiatry and Behavioral Sciences Research Center, Addiction Institute, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran

***Corresponding Author:** Raheleh Rafaiee, Emails: rachel.rafaie@yahoo.com, r.rafaie@mazums.ac.ir

Abstract

Substance abuse significantly impacts pulmonary health, with diverse complications arising from the use of tobacco, alcohol, opioids, and other illicit drugs. These substances can directly damage lung tissue and exacerbate chronic respiratory diseases through mechanisms like oxidative stress, inflammation, and immune dysfunction. This study reviewed current evidence on the prevalence, pathophysiology, and clinical manifestations of pulmonary complications associated with substance abuse. Key findings include the high prevalence of chronic obstructive pulmonary disease among heroin users, the association of cocaine with acute and chronic pulmonary conditions, and the role of alcohol in exacerbating respiratory infections and acute respiratory distress syndrome. The review highlights diagnostic challenges, emphasizing the need for comprehensive clinical assessments, advanced imaging, and biomarker utilization. Additionally, it outlines treatment strategies, including pharmacological interventions, smoking cessation programs, and pulmonary rehabilitation. Recognizing the public health implications, the review advocates preventive measures, harm reduction strategies, and integrated care models to mitigate the burden of substance-related pulmonary diseases.

Keywords: Substance abuse, Pulmonary complications, Respiratory diseases, Illicit drugs

Citation: Shahi F, Rafaiee R, Keikhaei N, Asadinejad Tahergourabi SH, Jomehpour H, Kalalian-Moghaddam H, et al. Pulmonary complications of substance abuse: pathophysiology, diagnosis, and management strategies. *Addict Health*. 2025;17:1641. doi:10.34172/ahj.1641

Received: November 30, 2024, **Revised:** January 10, 2025, **Accepted:** February 1, 2025, **ePublished:** October 2, 2025

Introduction

The global prevalence of drug use and drug-related deaths presents a significant public health challenge. According to the latest World Drug Report 2023 by the UNODC, approximately 5.8% of the global population aged 15 to 64—about 296 million people—reported using drugs in the past year.[1] This reflects a steady increase compared to previous years, with the global drug use burden continuing to grow. The UNODC report (2023) also highlights that drug use is linked to approximately 585,000 deaths annually worldwide. Opioids are the leading cause, accounting for two-thirds of drug-related deaths.[1] The percentage of addict deaths attributed to pulmonary problems varies significantly across different studies, reflecting the complex relationship between substance abuse and respiratory health. Long-term narcotic use leads to chronic pulmonary conditions, including fibrosis and vascular lesions, which can contribute to respiratory failure and death.[2] Acute respiratory distress and complications such as pulmonary edema and infections are common in drug-related deaths, particularly with intravenous drug use.[3] Acute alveolitis was found in 78% of heroin-related deaths and all methadone-related deaths, indicating a high incidence of pulmonary issues in these cases.[4] Necropsy studies revealed that 38% of crack cocaine users exhibited interstitial pneumonitis and pulmonary fibrosis, showcasing significant respiratory pathology.[5] A study indicated that 12% to 55% of cocaine users admitted with pulmonary complaints had abnormal chest radiographs, further emphasizing the respiratory impact of drug abuse.[6]

The significance of pulmonary health in the context

of substance use is underscored by the detrimental effects various substances have on lung function. Medical literature indicates that substance abuse, including marijuana, heroin, cocaine, and alcohol, leads to significant pulmonary complications, highlighting the need for awareness and intervention strategies.[7] A study found that 100% of substance users exhibited lung function abnormalities, with 80% showing obstructive lung disease.[8] While smoked marijuana is linked to chronic bronchitis, its long-term effects on pulmonary function remain inconclusive.[9] Heroin users exhibit high rates of Chronic Obstructive Pulmonary Disease (COPD), with estimates suggesting a 40% prevalence among users and up to 50% among smokers.[10] The risk of respiratory failure is heightened due to the respiratory depressant effects of opioids.[10] Cocaine use is associated with a wide range of acute and chronic pulmonary complications, including severe respiratory symptoms and conditions like pulmonary hypertension.[11] Addressing tobacco use among substance users is vital, as it exacerbates pulmonary health issues.[10]

Pulmonary complications of drug use and drug-related diseases are essential due to the significant health risks associated with various substances. The prevalence of respiratory issues among drug users highlights the need for comprehensive understanding and management strategies.[7] This review can inform clinical practices and improve patient outcomes by addressing the often-overlooked pulmonary health of these populations. Respiratory diseases in drug users are frequently underdiagnosed, leading to worsened health outcomes.[12] Late diagnosis of COPD among heroin users exacerbates disease progression, emphasizing the need for early identification.[3] Understanding these complications can guide clinicians in providing targeted interventions, such as regular respiratory function tests and tailored treatment plans for drug users.[13] Enhanced awareness can also improve compliance with treatment and reduce the stigma associated with seeking help for respiratory issues in this population.[10] This review aims to examine the pulmonary complications of substance abuse, focusing on their prevalence, mechanisms, diagnosis, management, and prevention strategies.

Substance Abuse and Pulmonary Health: Mechanisms of Injury

The pathophysiological mechanisms through which substances like tobacco, alcohol, and illicit drugs contribute to pulmonary injury are multifaceted, involving oxidative stress, inflammation, and direct cytotoxic effects on lung cells.[14] These mechanisms lead to various respiratory complications, highlighting the need for a comprehensive understanding of their impacts. Cigarette smoke is a primary pulmonary toxicant, causing oxidative stress and inflammation, which can lead to COPD and lung cancer.[15] The inhalation of harmful chemicals in tobacco smoke triggers inflammatory cascades, damaging lung tissue and exacerbating respiratory diseases.[15] Chronic ethanol exposure impairs alveolar macrophage function, leading to increased susceptibility to infections and lung injury.[16] Alcohol induces mitochondrial dysfunction and promotes the release of inflammatory mediators, contributing to pulmonary inflammation and injury.[16] Various illicit drugs, including opioids and methamphetamine (meth), can cause direct toxicity to lung cells, leading to conditions such as drug-induced lung injury.[17] The cytotoxic effects of drugs may involve reactive oxygen species and immune activation, resulting in significant pulmonary complications.[17, 18]

The impact of substance-induced inflammation, oxidative stress, and immune modulation on the lungs is profound, particularly in the context of chronic respiratory diseases. These factors interplay to exacerbate lung conditions, leading to significant morbidity and mortality. Inhalation of harmful substances, such as cigarette smoke, triggers oxidative stress by generating reactive oxygen species, which damage lung tissues and promote inflammation.[19] Chronic inflammation results in the release of pro-inflammatory cytokines, further perpetuating lung damage and contributing to diseases like COPD and asthma.[14] Oxidative stress disrupts normal immune responses, leading to an imbalance between pro-inflammatory and anti-inflammatory mechanisms.[14] This dysregulation can enhance susceptibility to infections and worsen chronic lung conditions, as seen in the impaired immune function associated with smoking.[20] Persistent oxidative stress can lead to modifications in the extracellular matrix, impairing lung function and promoting disease progression.[14] For instance, oxidative damage to extracellular matrix proteins can inhibit cell proliferation and increase inflammatory responses, further compromising lung integrity.[14] More detail about drug-induced lung damage and chronic pulmonary diseases is presented in Figure 1.

Pulmonary Complications Associated with Specific Substances

Pulmonary complications associated with tobacco and nicotine use are significant contributors to chronic respiratory diseases, including COPD, lung cancer, and emphysema. Tobacco smoke contains a complex mixture of harmful chemicals that exacerbate these conditions through various mechanisms. Tobacco smoke is the primary risk factor for COPD, leading to inflammation, mucus accumulation, and emphysema.[21] Electronic nicotine delivery systems have also been shown to exacerbate COPD features, including increased fibrosis and immune cell infiltration.[22] Smoking cessation is crucial, as it significantly reduces the risk of developing COPD and improves outcomes in affected individuals.[23]



Figure 1. Drug-induced cellular and molecular lung damage mechanisms and associated chronic pulmonary conditions

Tobacco use is a major cause of lung cancer, with the carcinogenic components of smoke playing a critical role in tumorigenesis.[24] Studies indicate that while nicotine itself may not directly cause lung cancer, the non-nicotine constituents of tobacco smoke are primarily responsible for this risk.[25] Emphysema, characterized by the destruction of alveolar walls, is directly linked to oxidative stress and inflammation caused by tobacco smoke.[21] The activation of nicotinic acetylcholine receptors in pulmonary tissues contributes to vascular dysfunction and may worsen emphysema.[21]

Alcohol consumption is linked to various pulmonary complications, including alcoholic lung disease, aspiration pneumonia, and acute respiratory distress syndrome (ARDS). These conditions arise from both the direct toxic effects of alcohol and its impact on immune function and lung architecture. Chronic alcohol abuse leads to significant morphological changes in lung tissue, including increased vascular permeability and accumulation of proteins, resulting in pneumosclerosis.[26] Alcohol impairs the function of alveolar macrophages, reducing their phagocytic activity and increasing susceptibility to infections.[26] Alcohol intoxication is a major risk factor for aspiration pneumonia, as it can impair the cough reflex and mucociliary clearance, allowing foreign particles to enter the lungs.[26] The combination of decreased immune reactivity and impaired protective mechanisms contributes to the development of aspiration-related lung injuries.[26, 27] Alcohol abuse significantly increases the risk of ARDS, with studies indicating a three- to four-fold increase in incidence.[28, 29] Mechanistically, alcohol enhances oxidative stress and inflammation in the lungs, exacerbating ARDS outcomes through pathways involving xanthine oxidoreductase and the NLRP3 inflammasome.[29]

Pulmonary complications associated with illicit drugs such as opioids, cocaine, and meth are diverse and can lead to significant morbidity and mortality. The complications arise from both direct toxic effects of the substances and indirect consequences related to substance use.[30] Opioids are well-known for causing respiratory depression, which can lead to hypoxia and respiratory failure due to their central nervous system depressant effects.[18] This condition is particularly dangerous in overdose situations, where the respiratory drive is significantly diminished. Cocaine and crack cocaine use can result in acute pulmonary edema, often characterized by fluid accumulation in the lungs, leading to severe respiratory distress.[31] This condition may occur due to increased vascular permeability and elevated pulmonary artery pressure. Users of illicit drugs, especially those who inject substances, are at high risk for pneumonia, often due to aspiration of vomit or contaminated substances.[32] The aggressive nature of drug-related pneumonia can lead to complications such as abscess formation and empyema.[32] Chronic use of stimulants can lead to interstitial lung disease and pulmonary fibrosis, with conditions like organizing pneumonia and eosinophilic pneumonia being reported.[31] These chronic conditions can result in long-term respiratory impairment and reduced quality of life.

The rise of vaping and e-cigarette use has raised significant concerns regarding pulmonary complications. Evidence indicates that these products can lead to various respiratory issues, including decreased lung function and specific lung injuries.[33] E-cigarette use is associated with a significant decrease in forced expiratory volume, indicating impaired lung function (SMD -0.18).[34] E-cigarette users exhibit increased odds of respiratory symptoms such as wheezing (OR 1.38) and chronic cough (OR 1.25).[34] E-cigarette or vaping product use-associated lung injury has emerged as a serious condition, particularly affecting adolescents, leading to ARDS.[35] Symptoms of the patients include cough, chest pain, and gastrointestinal issues, with some patients experiencing respiratory symptoms after prolonged e-cigarette use.[36] The increase in vaping among youth necessitates public health interventions, including education on the risks associated with e-cigarette use.[33, 35]

Comorbidities and Exacerbating Factors

Pre-existing lung conditions significantly exacerbate

the pulmonary complications associated with substance use. Individuals with conditions such as asthma, chronic bronchitis, or viral infections have a reduced respiratory reserve, making them more susceptible to the adverse effects of drugs. The interplay between these pre-existing conditions and substance use can lead to severe respiratory complications, necessitating a comprehensive understanding of both factors. Substance abuse can trigger asthma attacks, leading to acute respiratory distress and increased morbidity.[37] Drug users, particularly heroin smokers, exhibit high rates of COPD, which can worsen respiratory function and increase overdose risk.[10] Individuals with compromised lung function are more vulnerable to infections, which can be exacerbated by drug-related respiratory depression.[38] Drug abuse can precipitate acute respiratory failure, especially in those with chronic lung diseases, due to central nervous system depression and increased respiratory workload.[38] Drug users face higher rates of bacterial pneumonia and other infections, compounding the effects of pre-existing lung conditions.[37]

Patients with substance use are identified as a high-risk group for tuberculosis (TB), with studies indicating a higher incidence of both TB infection and active disease compared to the general population.[39] Drug use, particularly through shared equipment, facilitates TB transmission, especially in crowded living conditions.[39] Substance use can lead to immunosuppression, which exacerbates TB progression and complicates treatment outcomes.[40] Alterations in cytokine production due to drug use can impair immune responses, making individuals more susceptible to TB.[40] Diagnosing TB in patients with substance use is complicated by factors such as co-infection with HIV and hepatitis, which are prevalent in this population.[39] New diagnostic tools, such as the Xpert MTB/RIF test to detect TB and rifampicin resistance (an indicator of multidrug-resistant TB), have shown promise in improving TB detection among drug users. However, treatment adherence remains a challenge due to the complexities of drug interactions and side effects.[39]

The impact of coronavirus infection during the pandemic on lung problems in individuals with substance use has been significant. Those with pre-existing lung issues, exacerbated by addiction, face heightened risks of severe COVID-19 outcomes and persistent respiratory complications post-infection.[37] This intersection of COVID-19 and addiction has created a public health crisis that necessitates urgent attention.

Individuals with substance use, particularly opioid and meth users, are more susceptible to severe COVID-19 due to compromised lung function.[41] The COVID-19 pandemic has led to increased isolation and stress, contributing to relapses and new addictive behaviors.[42] Common post-COVID symptoms include breathlessness, cough, and impaired lung function, affecting the quality of life.[41] The prevalence of interstitial lung damage in post hospital COVID-19 survivors ranges from 5-11%, which can be particularly detrimental for those with substance use.[41] The COVID-19 pandemic has restricted access to addiction treatment services, complicating recovery for those with substance use.[43] Increased reliance on illegal means to procure substances has been reported, further endangering lung health.[42]

Environmental factors, particularly air pollution and occupational exposures, significantly influence substance-induced pulmonary damage. These factors contribute to various respiratory diseases through mechanisms such as oxidative stress, inflammation, and tissue remodeling. Understanding these influences is crucial for developing effective prevention and treatment strategies. Short- and long-term exposure to particulate matter 2.5 (PM2.5) is linked to asthma exacerbations, COPD, and lung cancer, even at low concentrations.[44] Exposure to nitrogen dioxide (NO2) correlates with increased mortality in patients with idiopathic pulmonary fibrosis. [45] Traditional occupational pollutants like asbestos and crystalline silica are known to cause severe lung diseases, including asbestosis and silicosis.[44] Various irritants in occupational settings contribute to the rising incidence of work-related asthma,[44] exacerbating the pulmonary complications associated with substance abuse.

Diagnosis and Clinical Presentation

Substance abuse can lead to a variety of pulmonary complications, manifesting through common respiratory symptoms. These symptoms often arise from both the direct toxicity of the substances and indirect effects on lung function. Clinicians must be vigilant in recognizing these symptoms, as they can indicate serious underlying conditions related to substance misuse. Cough and dyspnea are frequent in users of cocaine and other inhaled substances, often due to airway irritation and pulmonary edema.[18] Hemoptysis is notably associated with cocaine use, where diffuse alveolar hemorrhage can occur, leading to coughing up blood.[46] Wheezing and chest tightness result from bronchospasm and airway inflammation, particularly in users of marijuana and other inhalants.[47] Acute respiratory failure is common in substance abusers, especially those with pre-existing lung conditions. It can result from central nervous system depression or direct pulmonary injury.[38] Complications are often exacerbated in cases of polysubstance abuse, leading to a higher risk of respiratory failure.[38]

Clinical history and physical examination are vital for identifying risk factors and correlating symptoms with potential drug-related pulmonary diseases. Clinicians must maintain a high index of suspicion, especially when symptoms are nonspecific.[48, 49] Symptoms often resemble those of other respiratory conditions, complicating

the diagnostic process.[50] There is no definitive test for diagnosing drug-induced respiratory diseases, leading to reliance on exclusionary diagnoses.[50] The absence of specific biomarkers or imaging techniques further complicates accurate diagnosis.[51] Diagnostic strategies for substance-related pulmonary diseases encompass a variety of methods, including imaging techniques, pulmonary function tests, biomarkers, and clinical assessments. These approaches are crucial for accurate diagnosis, given the nonspecific nature of symptoms associated with these diseases.

Chest radiography is often the first imaging test, though it has low sensitivity and specificity for underlying etiologies. Computed tomography is more sensitive than radiography and can identify specific lung diseases and assess structural changes.[49] Advanced imaging techniques like dynamic chest radiography, MRI, and PET/CT are used for detailed functional analysis, including ventilation and perfusion assessments.[52] Pulmonary function tests measure lung capacity and airflow, helping to identify obstructive or restrictive patterns indicative of specific pulmonary diseases. They are essential for differentiating between various conditions, such as COPD and asthma.[52] Biomarkers are increasingly recognized for their role in diagnosing drug-induced pulmonary disorders, providing insights into the underlying pathophysiology. Specific biomarkers can indicate inflammation or fibrosis, aiding in the diagnosis of substance-related lung diseases.[53]

Diagnosing substance-related pulmonary diseases presents several challenges due to the complexity of symptoms, overlapping conditions, and the variety of substances involved. Clinicians must navigate these difficulties to accurately identify and treat respiratory complications associated with substance use. Many patients use multiple substances concurrently, making it difficult to attribute respiratory issues to a single drug.[54] This poly-drug use can obscure the clinical picture, as different substances may interact and exacerbate pulmonary conditions.[18]

Management and Treatment Strategies

Pharmacological management of acute and chronic substance-related pulmonary conditions involves a multifaceted approach that addresses both the immediate and long-term needs of patients. This management is crucial due to the significant respiratory complications associated with substance use, which can arise from direct toxicity or indirect effects of various substances. Bronchodilators are essential for immediate relief during acute exacerbations of respiratory distress, particularly in conditions like asthma and COPD.[55] Short-acting beta-agonists are commonly used. Systemic corticosteroid short courses (5 days) have been shown to be effective in managing acute exacerbations, providing rapid anti-inflammatory effects. Antibiotics targeted use is recommended for exacerbations associated with bacterial infections, depending on the severity of the condition.[55, 56] Long-term bronchodilator therapy with long-acting beta-agonists and anticholinergics is crucial for maintaining lung function and improving quality of life in chronic conditions.[57] Inhaled corticosteroids are used to reduce inflammation and prevent exacerbations, although their role is still under investigation.

Respiratory rehabilitation and supportive care play a vital role in managing substance-related pulmonary conditions, particularly in COPD. These interventions enhance patients' functional capacity, improve quality of life, and facilitate better management of symptoms. The integration of oxygen therapy and noninvasive ventilation into rehabilitation programs significantly augments the benefits of physical training, leading to improved exercise performance and reduced dyspnea. Pulmonary rehabilitation programs have been shown to enhance exercise capacity and reduce symptoms of dyspnea in COPD patients.[58] Pulmonary rehabilitation includes education on self-management strategies, which empowers patients to engage in physical activity and manage their condition effectively.[58] Supplemental oxygen, even for nonhypoxemic patients, allows for higher-intensity exercise, leading to better outcomes in terms of exercise capacity and quality of life.[58] Noninvasive ventilation has been associated with significant improvements in exercise performance and arterial blood gas levels, particularly in severe COPD cases.[59]

Treatment approaches for conditions such as COPD, aspiration pneumonia, and drug-induced pulmonary injury vary significantly based on the underlying pathology and patient needs. Each condition requires tailored interventions to optimize patient outcomes. Table 1 summarizes the key pulmonary complications, underlying mechanisms, and management strategies associated with various substances.

Smoking cessation, alcohol moderation, and opioid substitution therapies are critical components of comprehensive care for patients experiencing drug-induced pulmonary injury. These interventions address the multifaceted nature of substance use disorders and their impact on pulmonary health. Approximately 85% of patients on opioid agonist therapy also smoke tobacco, significantly increasing their risk of pulmonary diseases.[60, 61] Integrated smoking cessation programs, which include behavioral interventions and nicotine replacement therapies, have shown promise in improving smoking cessation rates among these patients.[61] Smoking exacerbates substance use, as nicotine can trigger cravings for other substances, complicating recovery efforts.[62]

Alcohol use disorders are prevalent among individuals with drug dependencies, and excessive alcohol consumption can worsen pulmonary health. Moderation strategies, including counseling and support groups,

Table 1. Pulmonary Complications Associated with Substance Abuse

Substance	Key Pulmonary Complications	Mechanisms of Injury	Management Strategies
Tobacco/Nicotine	COPD, lung cancer, emphysema	Oxidative stress, chronic inflammation, carcinogen-induced DNA damage	Smoking cessation, bronchodilators, pulmonary rehabilitation
Alcohol	Aspiration pneumonia, ARDS, alcoholic lung disease	Impaired macrophage function, increased vascular permeability, mitochondrial dysfunction	Moderation programs, supportive care, treatment of infections
Opioids	Respiratory depression, hypoxia, increased risk of infections	Central nervous system depression, reduced respiratory drive	Naloxone for acute overdose, opioid agonist therapy, oxygen therapy
Cocaine	Pulmonary edema, pulmonary hypertension, diffuse alveolar hemorrhage	Vascular permeability increase, oxidative stress, inflammatory response	Supportive care, vasodilators for pulmonary hypertension
Marijuana	Chronic bronchitis, potential COPD	Airway inflammation, immune modulation	Symptom management, education on risks
E-Cigarettes/ Vaping	EVALI, decreased lung function, chronic cough	Chemical-induced lung injury, oxidative stress, lipid-laden macrophages	Cessation, supportive care for EVALI, education on safe practices
Methamphetamine	Interstitial lung disease, pulmonary fibrosis, organizing pneumonia	Direct cytotoxicity, oxidative stress	Antioxidant therapy, symptom management
Polysubstance Use	Exacerbated pulmonary complications, a higher risk of respiratory infections	Combined toxic effects, impaired immune response	Integrated care addressing all substances, respiratory function monitoring
Environmental Factors	Exacerbation of asthma, COPD, and other lung diseases	Synergistic damage from particulate matter, nitrogen dioxide, and substance-induced lung injury	Avoidance of pollutants, workplace safety measures, targeted therapies

are essential for reducing alcohol intake and improving overall health outcomes.[63] Agonist replacement therapy (e.g., MMT or methadone maintenance treatment) is a standard treatment for opioid dependence, helping to stabilize patients and reduce illicit drug use.[64] Combining MMT with smoking cessation and alcohol moderation strategies enhances treatment adherence and overall health, particularly in managing drug-induced pulmonary injuries.

Prevention and Public Health Implications

Preventing pulmonary complications related to substance abuse requires a multifaceted approach that includes education, harm reduction, and early intervention. These strategies aim to mitigate the health risks associated with substance use, particularly concerning respiratory health. Educating individuals about the respiratory risks associated with specific substances, such as cocaine and opiates, can empower them to make informed choices.[18] Clinicians should be trained to recognize the signs of pulmonary complications in substance users, ensuring timely diagnosis and treatment.[65] Needle and syringe program initiatives reduce the risk of infections and pulmonary complications from intravenous drug use by providing sterile equipment.[66] Supervised consumption facilities can help monitor users and provide immediate medical assistance in case of respiratory distress.[66] Regular health screenings for substance users can identify early signs of pulmonary issues, allowing for prompt intervention. Addressing both substance use and respiratory health in a coordinated manner can improve outcomes for individuals with dual diagnoses.[65]

The role of policy and regulation in mitigating drug-induced injuries and health impacts is significant, encompassing legislative measures, community interventions, and regulatory frameworks. Effective policies, such as smoking bans and drug regulations, are crucial in reducing substance abuse and protecting public health. Comprehensive smoking bans have significantly decreased smoking rates and protected non-smokers from second-hand smoke exposure.[67] Increased taxation on tobacco products has proven effective in reducing consumption, particularly among youth.[67] Public awareness campaigns have successfully shifted social norms regarding tobacco use.[67] Addressing structural vulnerabilities through harm reduction strategies, such as decriminalization and safer supply initiatives, can mitigate health risks for vulnerable populations.[68]

Emerging Trends and Research Directions

Recent advances in understanding the pulmonary complications of substance abuse highlight several promising trends and areas for further exploration. The development of noninvasive diagnostic tools, such as advanced imaging techniques and biomarker-based assays, is enabling earlier and more accurate identification of respiratory conditions in substance users. Research into the long-term effects of vaping and e-cigarettes is also expanding, with studies investigating their role in conditions like e-cigarette, or vaping, product use-associated lung injury, and chronic respiratory disease. Furthermore, there is growing interest in personalized medicine approaches, which tailor interventions based on an individual's substance use patterns, genetic predispositions, and comorbidities.

On a public health level, harm reduction strategies, including safer consumption initiatives and integrated care models, are gaining traction to mitigate respiratory health risks. Emerging evidence also underscores the importance of addressing environmental and occupational exposures as compounding factors in substance-induced lung injuries. Future research should prioritize longitudinal studies to elucidate causal relationships, innovative treatments to reverse lung damage, and strategies to

reduce stigma, which remains a significant barrier to care in this population. By addressing these gaps, the medical community can better manage and prevent the pulmonary impacts of substance abuse.

Conclusion

Substance abuse poses a significant and often under-recognized threat to pulmonary health, contributing to a spectrum of acute and chronic respiratory complications. The interplay of direct cytotoxic effects, oxidative stress, and immune dysfunction underscores the complex pathophysiology underlying these conditions. From opioid-induced respiratory depression to chronic lung damage associated with tobacco, alcohol, and illicit drug use, the burden on affected individuals and healthcare systems is substantial. Accurate diagnosis remains challenging, necessitating advanced diagnostic tools and a high index of suspicion among clinicians. Effective management requires a multidisciplinary approach, integrating pharmacological treatments, smoking cessation programs, pulmonary rehabilitation, and harm reduction strategies. Prevention efforts, including public health education, policy interventions, and early screening, are critical to addressing the dual crises of substance abuse and respiratory disease. Future research should prioritize identifying biomarkers for early detection, optimizing treatment protocols, and developing targeted interventions to mitigate the pulmonary impacts of substance use. By fostering greater awareness and coordinated care, it is possible to improve outcomes and quality of life for this vulnerable population.

Acknowledgments

The authors wish to thank Mazandaran University of Medical Sciences.

Authors' Contribution

Conceptualization: Fariba Shahi.
Funding acquisition: Raheleh Rafaiee.
Supervision: Raheleh Rafaiee.
Investigation: Roya Rafaiee, Hamid Jomehpour, Mohammad Niroumand Sarvandani.
Methodology: Niloofar Keikhaei, Seyedeh Hatameh Asadinejad Tahergourabi, Raheleh Rafaiee.
Writing – original draft: Hamid Kalalian-Moghaddam.
Writing – review & editing: All Authors.

Competing Interests

No potential conflicts of interest were reported by the authors.

Ethical Approval

Not applicable.

Funding

This research was funded by a specific project grant from Mazandaran University of Medical Sciences (Project No.: 23397).

References

1. UNODC. World Drug Report 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/opioid-overdose.
2. Fuster D, Zuluaga P, Muga R. Substance use disorder: epidemiology, medical consequences and treatment. Med Clin (Engl Ed). 2024;162(9):431-8. doi: 10.1016/j.medcle.2023.11.021.
3. Mégarbane B, Chevillard L. The large spectrum of pulmonary complications following illicit drug use: features and mechanisms. Chem Biol Interact. 2013;206(3):444-51. doi: 10.1016/j.cbi.2013.10.011.
4. Jung H, Matei D, Pollak S, Jung I. Acute pulmonary alveolitis in narcotics-related deaths. Rom J Leg Med. 2008;16(4):247-52. doi: 10.4323/rjlm.2008.247.
5. Haim DY, Lippmann ML, Goldberg SK, Walkenstein MD. The pulmonary complications of crack cocaine. A comprehensive review. Chest. 1995;107(1):233-40. doi: 10.1378/chest.107.1.233.
6. Challita S, Daher M, Roche N, Alifano M, Revel MP, Rabbat A. Pneumorachis after cocaine sniffing. Respir Med Case Rep. 2014;12:10-2. doi: 10.1016/j.rmcr.2013.12.011.
7. Charuni Thennakoon J. Narrative review on the spectrum of diseases prevalent among substance-addicted populations and their interconnected health dynamics. J Sci Univ Kelaniya. 2024;17(1):57063. doi: 10.4038/josuk.v17i1.8107.
8. Mohamed HS, Ali IA. Comparative study of pulmonary functions test among different substances abusers. BMC Pulm Med. 2023;23(1):452. doi: 10.1186/s12890-023-02760-6.
9. Bando JM, Tashkin DP, Barjaktarevic IZ. Impact of marijuana use on lung health. Semin Respir Crit Care Med. 2024;45(5):548-59. doi: 10.1055/s-0044-1785679.
10. Darke S, Farrell M, Duflou J, Lappin J. Chronic obstructive pulmonary disease in heroin users: an underappreciated issue with clinical ramifications. Addiction. 2024;119(7):1153-5. doi: 10.1111/add.16407.
11. Restrepo CS, Carrillo JA, Martínez S, Ojeda P, Rivera AL, Hatta A. Pulmonary complications from cocaine and cocaine-based substances: imaging manifestations. Radiographics. 2007;27(4):941-56. doi: 10.1148/rg.274065144.
12. Wu LT, Zhu H, Ghitza UE. Multicomorbidity of chronic diseases and substance use disorders and their association with hospitalization: results from electronic health records data. Drug Alcohol Depend. 2018;192:316-23. doi: 10.1016/j.drugalcdep.2018.08.013.
13. Dennett EJ, Janjua S, Stovold E, Harrison SL, McDonnell MJ, Holland AE. Tailored or adapted interventions for adults with chronic obstructive pulmonary disease and at least one other long-term condition: a mixed methods review. Cochrane Database Syst Rev. 2021;7(7):CD013384. doi: 10.1002/14651858.CD013384.pub2.
14. Bezerra FS, Lanzetti M, Nesi RT, Nagato AC, Pecli E Silva C, Kennedy-Feitosa E, et al. Oxidative stress and inflammation in acute and chronic lung injuries. Antioxidants (Basel). 2023;12(3):548. doi: 10.3390/antiox12030548.
15. Cha SR, Jang J, Park SM, Ryu SM, Cho SJ, Yang SR. Cigarette smoke-induced respiratory response: insights into cellular processes and biomarkers. Antioxidants (Basel). 2023;12(6):1210. doi: 10.3390/antiox12061210.
16. Traphagen N, Tian Z, Allen-Gipson D. Chronic ethanol exposure: pathogenesis of pulmonary disease and dysfunction. Biomolecules. 2015;5(4):2840-53. doi: 10.3390/biom5042840.
17. Ramirez RL 3rd, Perez VJ, Zamanian RT. Methamphetamine and the risk of pulmonary arterial hypertension. Curr Opin Pulm Med. 2018;24(5):416-24. doi: 10.1097/mcp.0000000000000513.
18. Nanayakkara B, McNamara S. Respiratory problems and substance misuse. In: El-Guebaly N, Carrà G, Galanter M, Baldacchino AM, eds. Textbook of Addiction Treatment:

International Perspectives. Cham: Springer International Publishing; 2021. p. 1045-59. doi: 10.1007/978-3-030-36391-8_74.
19. Foronjy R, D'Armiento J. The effect of cigarette smoke-derived oxidants on the inflammatory response of the lung. Clin Appl Immunol Rev. 2006;6(1):53-72. doi: 10.1016/j.cair.2006.04.002.
20. Qiu F, Liang CL, Liu H, Zeng YQ, Hou S, Huang S, et al. Impacts of cigarette smoking on immune responsiveness: up and down or upside down? Oncotarget. 2017;8(1):268-84. doi: 10.18632/oncotarget.13613.
21. Lu W, Aarsand R, Schotte K, Han J, Lebedeva E, Tsoy E, et al. Tobacco and COPD: presenting the World Health Organization (WHO) tobacco knowledge summary. Respir Res. 2024;25(1):338. doi: 10.1186/s12931-024-02961-5.
22. Han H, Peng G, Meister M, Yao H, Yang JJ, Zou MH, et al. Electronic cigarette exposure enhances lung inflammatory and fibrotic responses in COPD mice. Front Pharmacol. 2021;12:726586. doi: 10.3389/fphar.2021.726586.
23. Au DH, Bryson CL, Chien JW, Sun H, Udris EM, Evans LE, et al. The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations. J Gen Intern Med. 2009;24(4):457-63. doi: 10.1007/s11606-009-0907-y.
24. Hecht SS. Lung carcinogenesis by tobacco smoke. Int J Cancer. 2012;131(12):2724-32. doi: 10.1002/ijc.27816.
25. Khouja JN, Sanderson E, Wootton RE, Taylor AE, Church BA, Richmond RC, et al. Estimating the health impact of nicotine exposure by dissecting the effects of nicotine versus non-nicotine constituents of tobacco smoke: a multivariable Mendelian randomisation study. PLoS Genet. 2024;20(2):e1011157. doi: 10.1371/journal.pgen.1011157.
26. Boé DM, Vandivier RW, Burnham EL, Moss M. Alcohol abuse and pulmonary disease. J Leukoc Biol. 2009;86(5):1097-104. doi: 10.1189/jlb.0209087.
27. Davydova ZV, Yagmurov OD. [Morphofunctional characteristic of the microvasculature of the lung tissue in acute fatal ethanol poisoning]. Sud Med Ekspert. 2020;63(4):17-21. doi: 10.17116/sudmed20206304117. [Russian].
28. Solopov PA, Colunga Biancatelli RM, Dimitropolou C, Catravas JD. Alcohol exacerbates SARS-CoV-2-induced ARDS in mice. FASEB J. 2022;36(S1). doi: 10.1096/fasebj.2022.36.S1.R4613.
29. Fini MA, Gaydos J, McNally A, Karoor V, Burnham EL. Alcohol abuse is associated with enhanced pulmonary and systemic xanthine oxidoreductase activity. Am J Physiol Lung Cell Mol Physiol. 2017;313(6):L1047-57. doi: 10.1152/ajplung.00570.2016.
30. Fox TP, Oliver G, Ellis SM. The destructive capacity of drug abuse: an overview exploring the harmful potential of drug abuse both to the individual and to society. ISRN Addict. 2013;2013:450348. doi: 10.1155/2013/450348.
31. Ziani H, Nasri S, Kamaoui I, Skiker I. Cocaine-induced lung damage and uncommon involvement of the basal ganglia. Cureus. 2024;16(1):e53330. doi: 10.7759/cureus.53330.
32. Lavender TW, McCarron B. Acute infections in intravenous drug users. Clin Med (Lond). 2013;13(5):511-3. doi: 10.7861/clinmedicine.13-5-511.
33. Casey AM, Muise ED, Crotty Alexander LE. Vaping and e-cigarette use. Mysterious lung manifestations and an epidemic. Curr Opin Immunol. 2020;66:143-50. doi: 10.1016/j.coi.2020.10.003.
34. Florensia R, Fauzar, Kurniati R. A meta-analysis of electric cigarette use and lung health implications. Biosci Med J Biomed Transl Res. 2024;8(10):5160-71. doi: 10.37275/bsm.v8i10.1099.
35. Veković V, Živković Z. E cigarettes and adolescents. Preventive Paediatrics. 2024;10(1-2):11-4. doi: 10.46793/pp240116002v.
36. dos Santos PG, Silva LB, Travassos RM, de Ataíde Filho AC, de Queiroz Marques Filho E, Ataíde JP, et al. The electronic cigarette trend: the impacts on oral health. Aracê. 2024;6(1):2-14. doi: 10.56238/arev6n1-001.
37. Balaram K, Marwaha R, Kaelber DC. The effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes. Curr Opin Psychiatry. 2021;34(4):386-92. doi: 10.1097/yco.0000000000000711.
38. Wilson KC, Saukkonen JJ. Acute respiratory failure from abused substances. J Intensive Care Med. 2004;19(4):183-93. doi: 10.1177/0885066604263918.
39. Grenfell P, Baptista Leite R, Garfein R, de Lussigny S, Platt L, Rhodes T. Tuberculosis, injecting drug use and integrated HIV-TB care: a review of the literature. Drug Alcohol Depend. 2013;129(3):180-209. doi: 10.1016/j.drugalcdep.2012.11.013.
40. Kiboi NG, Nebere SN, Karanja JK. Immunological interactions of tuberculosis with drugs and substance use: a systematic review and update. J Pulm Respir Med.2016;6(2):326. doi: 10.4172/2161-105x.1000326.
41. Volkow ND. Collision of the COVID-19 and addiction epidemics. Ann Intern Med. 2020;173(1):61-2. doi: 10.7326/m20-1212.
42. Dubey MJ, Ghosh R, Chatterjee S, Biswas P, Chatterjee S, Dubey S. COVID-19 and addiction. Diabetes Metab Syndr. 2020;14(5):817-23. doi: 10.1016/j.dsx.2020.06.008.
43. Columb D, Hussain R, O'Gara C. Addiction psychiatry and COVID-19: impact on patients and service provision. Ir J Psychol Med. 2020;37(3):164-8. doi: 10.1017/ipm.2020.47.
44. Nishida C, Yatera K. The impact of ambient environmental and occupational pollution on respiratory diseases. Int J Environ Res Public Health. 2022;19(5):2788. doi: 10.3390/ijerph19052788.
45. Yoon HY, Kim SY, Kim OJ, Song JW. Nitrogen dioxide increases the risk of mortality in idiopathic pulmonary fibrosis. Eur Respir J. 2021;57(5):2001877. doi: 10.1183/13993003.01877-2020.
46. de Almeida RR, Zanetti G, Souza AS Jr, de Souza LS, Pereira e Silva JL, Escuissato DL, et al. Cocaine-induced pulmonary changes: HRCT findings. J Bras Pneumol. 2015;41(4):323-30. doi: 10.1590/s1806-37132015000000025.
47. Ribeiro L, Ind PW. Marijuana and the lung: hysteria or cause for concern? Breathe (Sheff). 2018;14(3):196-205. doi: 10.1183/20734735.020418.
48. Conte P, Ascierto PA, Patelli G, Danesi R, Vanzulli A, Sandomenico F, et al. Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. ESMO Open. 2022;7(2):100404. doi: 10.1016/j.esmoop.2022.100404.
49. Oliva IB, Cortopassi F, Rubinowitz AN. Clinical characteristics and imaging features of smoking-related lung diseases. Clin Pulm Med. 2014;21(2):86-95. doi: 10.1097/cpm.0000000000000026.
50. Mustafaoglu R, Görek Dilektaşlı A, Demir R, Zirek E, Birinci T, Kaya Mutlu E, et al. The effects of substance use disorder on respiratory function parameters and functional capacity in Istanbul. Eur Respir J. 2020;56(Suppl 64):1880. doi: 10.1183/13993003.congress-2020.1880.
51. Libu C, Otelea MR, Arghir IA, Rascu A, Antoniu SA, Arghir OC. Challenges in diagnosing occupational chronic obstructive pulmonary disease. Medicina (Kaunas). 2021;57(9):911. doi: 10.3390/medicina57090911.
52. Nakamura H, Hirai T, Kurosawa H, Hamada K, Matsunaga K, Shimizu K, et al. Current advances in pulmonary functional imaging. Respir Investig. 2024;62(1):49-65. doi: 10.1016/j.

resinv.2023.09.004.
53. Zheng Z, Peng F, Zhou Y. Biomarkers in idiopathic pulmonary fibrosis: current insight and future direction. Chin Med J Pulm Crit Care Med. 2024;2(2):72-9. doi: 10.1016/j.pccm.2024.04.003.
54. Tseng W, Sutter ME, Albertson TE. Stimulants and the lung: review of literature. Clin Rev Allergy Immunol. 2014;46(1):82-100. doi: 10.1007/s12016-013-8376-9.
55. Sarkar S, Bhatia G, Dhawan A. Clinical practice guidelines for assessment and management of patients with substance intoxication presenting to the emergency department. Indian J Psychiatry. 2023;65(2):196-211. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_490_22.
56. Nacul L, Soljak M, Samarasundera E, Hopkinson NS, Lacerda E, Indulkar T, et al. COPD in England: a comparison of expected, model-based prevalence and observed prevalence from general practice data. J Public Health (Oxf). 2011;33(1):108-16. doi: 10.1093/pubmed/fdq031.
57. Braido F, Baiardini I, Cazzola M, Brusselle G, Marugo F, Canonica GW. Long-acting bronchodilators improve health related quality of life in patients with COPD. Respir Med. 2013;107(10):1465-80. doi: 10.1016/j.rmed.2013.08.007.
58. ZuWallack R, Hedges H. Primary care of the patient with chronic obstructive pulmonary disease-part 3: pulmonary rehabilitation and comprehensive care for the patient with chronic obstructive pulmonary disease. Am J Med. 2008;121(7 Suppl):S25-32. doi: 10.1016/j.amjmed.2008.04.004.
59. Chen X, Xu L, Li S, Yang C, Wu X, Feng M, et al. Efficacy of respiratory support therapies during pulmonary rehabilitation exercise training in chronic obstructive pulmonary disease patients: a systematic review and network meta-analysis. BMC Med. 2024;22(1):389. doi: 10.1186/s12916-024-03605-7.
60. Maruyama A, Macdonald S, Borycki E, Zhao J. Hypertension, chronic obstructive pulmonary disease, diabetes and depression among older methadone maintenance patients in British Columbia. Drug Alcohol Rev. 2013;32(4):412-8. doi: 10.1111/dar.12031.
61. Druckrey-Fiskaaen KT, Furulund E, Daltveit JT, Vold JH, Lid TG, Madebo T, et al. Integration of smoking cessation into standard treatment for patients receiving opioid agonist therapy who are smoking tobacco: protocol for a randomised controlled trial (ATLAS4LAR). Trials. 2022;23(1):663. doi: 10.1186/s13063-022-06560-x.
62. Rhodes BE, Gottfredson NC. Effects of tobacco on affect and craving during opioid addiction recovery: an ecological momentary assessment study. Addict Behav. 2020;106:106358. doi: 10.1016/j.addbeh.2020.106358.
63. Kaner EF, Beyer FR, Muirhead C, Campbell F, Pienaar ED, Bertholet N, et al. Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database Syst Rev. 2018;2(2):CD004148. doi: 10.1002/14651858.CD004148.pub4.
64. Maremmani AGI, Pacini M, Maremmani I. What we have learned from the methadone maintenance treatment of dual disorder heroin use disorder patients. Int J Environ Res Public Health. 2019;16(3):447. doi: 10.3390/ijerph16030447.
65. Volkow ND, Blanco C. Substance use disorders: a comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention. World Psychiatry. 2023;22(2):203-29. doi: 10.1002/wps.21073.
66. Resiak D, Mpofu E, Rothwell R. Sustainable harm reduction needle and syringe programs for people who inject drugs: a scoping review of their implementation qualities. Sustainability. 2021;13(5):2834. doi: 10.3390/su13052834.
67. Alonazi M. Impact of smoking on resin bonded restorations: a narrative review. Tob Induc Dis. 2024;22. doi: 10.18332/tid/188114.
68. Gehring ND, Speed KA, Wild TC, Pauly B, Salvalaggio G, Hyshka E. Policy actor views on structural vulnerability in harm reduction and policymaking for illegal drugs: a qualitative study. Int J Drug Policy. 2022;108:103805. doi: 10.1016/j.drugpo.2022.103805.